VTechWorks staff will be away for the Thanksgiving holiday beginning at noon on Wednesday, November 27, through Friday, November 29. We will resume normal operations on Monday, December 2. Thank you for your patience.
 

Newer antipsychotics: Brexpiprazole, cariprazine, and lumateperone: A pledge or another unkept promise?

Simple item page
dc.contributor.authorBarman, Rajdipen
dc.contributor.authorMajumder, Pradiptaen
dc.contributor.authorDoifode, Tejaswinien
dc.contributor.authorKablinger, Anita S.en
dc.date.accessioned2022-04-15T17:54:52Zen
dc.date.available2022-04-15T17:54:52Zen
dc.date.issued2021-12-19en
dc.date.updated2022-04-15T17:44:44Zen
dc.description.abstractAntipsychotic agents are used for various indications in the treatment of psychiatric disorders. Despite their proven roles in multiple conditions, the treatment-emergent side effects of antipsychotic medications, such as metabolic side effects, are often the limiting factor for their long-term and short-term uses. Moreover, antipsychotic medications are often criticized for being less effective in treating different disabling symptoms such as negative symptoms of schizophrenia. As a result, the search for safer and more efficacious antipsychotic agents is ongoing. Newer antipsychotic agents are gaining attention related to emerging efficacy and tolerability data in treating neuropsychiatric conditions. In this review, we attempt to appraise the scientific data on psychopharmacology, safety profile, and efficacy of the newer additions to the list of second-generation antipsychotics, namely brexpiprazole, cariprazine, and lumateperone. We conducted a selective review utilizing PubMed, clinicaltrials.gov, and Cochrane databases to gather appropriate publications, keeping broad inclusion criteria. There were no restrictions on the age of the study population or the year of publication. We also cross-referenced articles and references to capture all existing studies. Our review of the current literature indicates that all three antipsychotic agents appear to be promising based on their short-term studies, while long-term studies remain limited. There is also a need for a head to head comparison between the newer antipsychotics with the other antipsychotic agents to ascertain if the newer agents are any better than the others.en
dc.description.versionPublished versionen
dc.format.extentPages 1228-1238en
dc.format.extent11 page(s)en
dc.format.mimetypeapplication/pdfen
dc.identifier.doihttps://doi.org/10.5498/wjp.v11.i12.1228en
dc.identifier.eissn2220-3206en
dc.identifier.issn2220-3206en
dc.identifier.issue12en
dc.identifier.orcidKablinger, Anita [0000-0002-7131-0036]en
dc.identifier.pmid35070772en
dc.identifier.urihttp://hdl.handle.net/10919/109678en
dc.identifier.volume11en
dc.language.isoenen
dc.publisherBaishidengen
dc.relation.urihttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000745664800005&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=930d57c9ac61a043676db62af60056c1en
dc.rightsCreative Commons Attribution-NonCommercial 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/en
dc.subjectPsychiatryen
dc.subjectAntipsychotic agenten
dc.subjectBrexpiprazoleen
dc.subjectCariprazineen
dc.subjectLumateperoneen
dc.subjectPsychopharmacologyen
dc.subjectSchizophreniaen
dc.subjectPREDOMINANT NEGATIVE SYMPTOMSen
dc.subjectMAJOR DEPRESSIVE DISORDERen
dc.subjectDOPAMINE D-3 RECEPTORen
dc.subjectDOUBLE-BLINDen
dc.subjectACUTE EXACERBATIONen
dc.subjectINADEQUATE RESPONSEen
dc.subjectACUTE SCHIZOPHRENIAen
dc.subjectEFFICACYen
dc.subjectSAFETYen
dc.subjectPHASE-3en
dc.subjectAntipsychotic agenten
dc.subjectBrexpiprazoleen
dc.subjectCariprazineen
dc.subjectLumateperoneen
dc.subjectPsychopharmacologyen
dc.subjectSchizophreniaen
dc.titleNewer antipsychotics: Brexpiprazole, cariprazine, and lumateperone: A pledge or another unkept promise?en
dc.title.serialWorld Journal of Psychiatryen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten
dc.type.otherJournalen
dcterms.dateAccepted2021-10-27en
pubs.organisational-group/Virginia Techen
pubs.organisational-group/Virginia Tech/Faculty of Health Sciencesen
pubs.organisational-group/Virginia Tech/VT Carilion School of Medicineen
pubs.organisational-group/Virginia Tech/VT Carilion School of Medicine/Psychiatry and Behavioral Medicineen
pubs.organisational-group/Virginia Tech/VT Carilion School of Medicine/Psychiatry and Behavioral Medicine/Psychiatry and Behavioral Medicineen

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Newer antipsychotics Brexpiprazole, cariprazine, and lumateperone A pledge or another unkept promise.pdf
Size:
453.01 KB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

All Faculty Deposits
Scholarly Works, Virginia Tech Carilion School of Medicine (VTCSOM)